- Conditions
- Healthy
- Interventions
- Virtual Promotoras Program
- Behavioral
- Lead sponsor
- University of Alabama, Tuscaloosa
- Other
- Eligibility
- 16 Years to 21 Years · Female only
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Tuscaloosa, Alabama
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 241–264
of 878
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Neuropathy;Peripheral, Limb Ischemia
- Interventions
- Lower-Extremity Perfusion Monitoring
- Other
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Airway Disease, Barrett Esophagus, Gastroesophageal Reflux Disease
- Interventions
- Not listed
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 37 Years to 90 Years · Male only
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Obesity, Surgery, Anesthesia
- Interventions
- no intervention
- Other
- Lead sponsor
- University of Vermont Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Burlington, Vermont
- Conditions
- Smoking, Nicotine Dependence
- Interventions
- No intervention: observation only
- Other
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 422 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2019
- U.S. locations
- 2
- States / cities
- Madison, Wisconsin • Milwaukee, Wisconsin
- Conditions
- Acute Cannabis-induced CNS Depression
- Interventions
- Not listed
- Lead sponsor
- Anebulo Pharmaceuticals
- Industry
- Eligibility
- Not listed
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 3
- States / cities
- Worcester, Massachusetts • Cincinnati, Ohio • Portland, Oregon
- Conditions
- Congenital Heart Disease, Cardiac Output, Hemodynamic Monitoring, Pediatric Heart Disease
- Interventions
- UltraTrac
- Device
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 0 Years to 80 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Neuroectodermal Tumors, Primitive, Liver Neoplasms, Osteosarcoma, Other Childhood Cancers Using Cisplatin-based Regimens
- Interventions
- N-Acetylcysteine
- Drug
- Lead sponsor
- Children's Hospital Los Angeles
- Other
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- HIV Infections, Cytomegalovirus Infections
- Interventions
- Valganciclovir, Placebo
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Incident Type 2 Diabetes, Incident Obesity
- Interventions
- No intervention in an observational study
- Other
- Lead sponsor
- Des Moines University
- Other
- Eligibility
- 40 Years to 60 Years · Male only
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Des Moines, Iowa
- Conditions
- Ocular Motility Disorders, Strabismus, Extraocular Muscle Dysfunction, Thyroid Eye Disease
- Interventions
- Glandy EOM (AI-based quantitative eye movement analysis software)
- Device
- Lead sponsor
- THYROSCOPE INC.
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- San Jose, California
- Conditions
- Cystic Fibrosis, Diabetes
- Interventions
- Once-daily insulin detemir
- Drug
- Lead sponsor
- Sydney Children's Hospitals Network
- Other
- Eligibility
- 5 Years to 19 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2023
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Substance Use Disorders
- Interventions
- Not listed
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 63 participants
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Colonic Neoplasms, Colorectal Neoplasms
- Interventions
- GRT-C901, GRT-R902, Atezolizumab, Ipilimumab, Adjuvant chemotherapy
- Drug
- Lead sponsor
- Gritstone bio, Inc.
- Industry
- Eligibility
- 12 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 3
- States / cities
- Detroit, Michigan • New York, New York • Cincinnati, Ohio
- Conditions
- Multiple Myeloma
- Interventions
- One Autologous Transplant, Non-Myeloablative Allogeneic Transplant, Second Autologous Transplant, Thalidomide, Dexamethasone, Observation
- Procedure · Drug · Behavioral
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- Up to 70 Years
- Enrollment
- 710 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2013
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 28 more
- Conditions
- Frontotemporal Degeneration, Progressive Supranuclear Palsy, Multiple System Atrophy
- Interventions
- None-Observation Only
- Other
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 997 participants
- Timeline
- 2003 – 2020
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Laparoscopic Hysterectomy
- Interventions
- Surgicel Snow, Standard of Care
- Device · Other
- Lead sponsor
- Danbury Hospital
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 43 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2019
- U.S. locations
- 3
- States / cities
- Danbury, Connecticut • Norwalk, Connecticut
- Conditions
- Triple Negative Breast Cancer
- Interventions
- adagloxad simolenin combined with OBI-821, Globo H IHC Assay, Standard of care treatment
- Biological · Device · Other
- Lead sponsor
- OBI Pharma, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 575 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 12
- States / cities
- La Jolla, California • San Diego, California • San Francisco, California + 9 more
- Conditions
- Maternal Behavior, Maternal Obesity, Breast Milk Collection, Infant Development
- Interventions
- Observational
- Other
- Lead sponsor
- University of Idaho
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Moscow, Idaho
- Conditions
- Obstructive Sleep Apnea, Sleep Apnea
- Interventions
- ProSomnus® EVO Sleep and Snore Device
- Device
- Lead sponsor
- ProSomnus Sleep Technologies
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 5
- States / cities
- Redwood City, California • Boston, Massachusetts • Minneapolis, Minnesota + 2 more
- Conditions
- Task Performance and Analysis, Efficiency
- Interventions
- Observation
- Other
- Lead sponsor
- University of Hawaii
- Other
- Eligibility
- Not listed
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Honolulu, Hawaii
- Conditions
- HIV
- Interventions
- Raltegravir
- Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Multiple Sclerosis
- Interventions
- Transcutaneous electrical spinal cord stimulation + therapy, Occupational Therapy
- Combination Product · Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Malignant Ovarian Brenner Tumor, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Stage IIA Fallopian Tube Cancer AJCC v6 and v7, Stage IIA Ovarian Cancer AJCC V6 and v7, Stage IIB Fallopian Tube Cancer AJCC v6 and v7, Stage IIB Ovarian Cancer AJCC v6 and v7, Stage IIC Fallopian Tube Cancer AJCC v6 and v7, Stage IIC Ovarian Cancer AJCC v6 and v7, Stage IIIA Fallopian Tube Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v6 and v7, Stage IIIA Primary Peritoneal Cancer AJCC v7, Stage IIIB Fallopian Tube Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v6 and v7, Stage IIIB Primary Peritoneal Cancer AJCC v7, Stage IIIC Fallopian Tube Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v6 and v7, Stage IIIC Primary Peritoneal Cancer AJCC v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7, Undifferentiated Fallopian Tube Carcinoma, Undifferentiated Ovarian Carcinoma
- Interventions
- Behavioral Dietary Intervention, Compliance Monitoring, Counseling, Educational Intervention, Exercise Intervention, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration
- Behavioral · Other
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,070 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2012
- U.S. locations
- 687
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 452 more